Integra LifeSciences Announces Launch of the Integra Brain Retractor System
PLAINSBORO, N.J., Jun 15, 2007 (PrimeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has launched the Integra Brain Retractor System. This new line extension, combined with the existing BUDDE(R) Halo System, allows Integra to offer neurosurgeons a comprehensive line of brain retractors. Like the BUDDE(R) Halo System, the new Integra Brain Retractor System attaches to standard MAYFIELD(R) skull clamps. The modular components of the Integra Brain Retraction System have a low-profile design that allows the neurosurgeon improved access to the surgical field. The design also provides easy and rapid set-up, as well as the flexibility of multiple configurations required for surrounding the surgical site, in a wide variety of neurosurgical procedures.
Neurosurgeons use brain retractor systems for the retraction of delicate brain tissue during complex neurosurgical procedures, such as tumor removal and aneurysm repair. "The Integra brain retractor product line now offers a full range of retraction solutions, and meets the majority of neurosurgeons' needs in the marketplace," said Jim McCafferty, Integra's Vice President of MAYFIELD(R) Marketing.
The Integra NeuroSciences direct sales organization will sell the Integra Brain Retractor System. Integra NeuroSciences is a leading provider of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related critical care. Integra NeuroSciences' direct selling effort in the United States and Europe involves more than 150 professionals. In all other markets, Integra NeuroSciences products are sold through a network of distributors.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (http://www.Integra-LS.com).
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the use of the Integra Brain Retractor System and the market for such products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use this product may affect the prospects for its use in clinical procedures and Integra Neurosciences' overall share in the market for such products. In addition, the economic, competitive, governmental, technological and other factors, identified in the Risk Factors section of Integra's Annual Report on Form 10-K for the year ended December 31, 2006, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.
"MAYFIELD" is a registered trademark of SM USA, Inc., a wholly owned subsidiary of Schaerer Mayfield USA, Inc., and is used by Integra under license.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Integra LifeSciences Holdings Corp.
Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President,
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com
Gianna Sabella, Public Relations Manager
(609) 936-2389
gsabella@integra-LS.com
(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.
News Provided by COMTEX